Dennis Phillip Andrew reported option exercise involving 23,695 shares of NovaBridge Biosciences on Sep 17, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Medical Officer
Chief Medical Officer
Filed Sep 21, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
—Shares × reported price
Shares traded
23,695Ordinary Shares
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
181,636Direct
Trade date
Sep 17, 2026Option exercise
Filed
Sep 21, 2026, 4:05 PM ET4-day reporting delay
Accession
0002089237-26-000008Code M · Transaction 226514
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 18, 2026Sell8,209$0.71−$5,828.39Trade 226515
Sep 17, 2026Option exercise10,302$0.00$0Trade 226516
3 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

NBP price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
NBP · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago +5%1d ago −2.5%
Returns since7d −16%30d −12%90d180d1y

Footnotes in full

F1: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F2: Reported securities are represented by 10,302 ADSs. F3: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. F4: Reported securities are represented by 78,972 ADSs. F5: Reported securities are represented by 3,569 ADSs. F6: Reported sales price represents the converted sales price of the ADSs of $1.6247. F7: Reported securities are represented by 75,403 ADSs. F8: Reported securities represent ADSs. F9: On June 17, 2024, the Reporting Person was granted 164,840 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 17th day of each third month.